If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Bristol-Myers Squibb terminated a real-world, non-interventional study on Ozanimod, targeting moderate-to-severe ulcerative ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

While current methods of isolating islet cells for transplantation strip away the structural scaffold that supports the cells ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Long-term follow-up data show that the preventive effects of short-term treatment with abatacept disappear after 4-5 years.

Ashish Patil stands at the forefront of this evolution, transforming logistics through innovation, decision intelligence, and ...